Loading
institutionsInstitution
Duke Cancer Institute
One of the original NCI comprehensive centres (1973), famous for brain tumour research including the polio-virus immunotherapy for glioblastoma.
Overview
Duke has held NCI comprehensive designation since 1973. The Preston Robert Tisch Brain Tumor Center, built by Darell Bigner, developed the recombinant polio-rhinovirus PVSRIPO oncolytic immunotherapy for recurrent glioblastoma and, with Hai Yan, helped define IDH mutations in glioma. Duke investigators helped lead pivotal HER2 breast cancer trials including EMILIA (trastuzumab emtansine), and its prostate programme (Andrew Armstrong, Daniel George) is a fixture of Alliance and NCI trials. The Duke Clinical Research Institute is the largest academic clinical research organisation in the world and runs many oncology trials. Michael Kastan's DNA-damage biology and dendritic cell vaccine work under Smita Nair anchor the basic and immunology programmes.
Location
Durham, NC, US
Type
cancer center · Duke University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#111 · 37 points (0 Newsweek + 15 NCI + 22 from 11 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Duke Cancer Institute, including child institutions. 546 works · 10,220 citations · 69% open access · 17% clinical trials · 1% reviews.
Oncology works per year
1082022
1142023
1262024
1092025
892026
Most works
- Thomas E. Stinchcombe42 works
- Andrew J. Armstrong28 works
- Carey K. Anders26 works
- Georgia Marie Beasley21 works
- Rebecca A. Previs20 works
- John H. Strickler18 works
- Shakti H Ramkissoon18 works
- Eric Allan Severson18 works
- Kyle C. Strickland18 works
- Jennifer Kay Plichta17 works
Most cited
- Neuro-oncology (Tisch Brain Tumor Center)
- Oncolytic virus immunotherapy
- Prostate cancer
- Clinical trials (DCRI)
Andrew J. Armstrong
Professor of Medicine, Surgery, and Pharmacology and Cancer Biology, Duke Cancer Institute
Prostate cancerAndrogen receptor inhibitorsBiomarkers of resistance
Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.
E. Shelley Hwang
Breast surgical oncologist, Duke Cancer Institute
Ductal carcinoma in situActive monitoringSurgical de-escalation
Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away.
John H. Strickler
Gastrointestinal medical oncologist, Duke Cancer Institute
HER2-amplified colorectal cancerTargeted therapyCirculating tumour DNA
Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer.
Scott J. Antonia
Director, Center for Cancer Immunotherapy, Duke Cancer Institute
Lung cancer immunotherapyStage III NSCLCTumour immunology
Led PACIFIC, which made a year of durvalumab after chemoradiation the standard for stage III lung cancer.
Similar pages
- IdeaDeliver drugs and cells to the brain through the nose
Shares Oncolytic viruses, The brain: barrier and sanctuary, Glioma & glioblastoma.
- TrialCOMET (Comparison of Operative versus Monitoring and Endocrine Therapy)
Shares E. Shelley Hwang, Alliance for Clinical Trials in Oncology.
- Key paperINDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma
Shares IDH1 / IDH2, The brain: barrier and sanctuary, Trial design, endpoints and cost, Glioma & glioblastoma.
- PersonEvanthia Galanis
Shares Alliance for Clinical Trials in Oncology, Oncolytic viruses, Glioma & glioblastoma.
- InstitutionUniversity of Florida Health Cancer Center
Shares The brain: barrier and sanctuary, National Cancer Institute (NIH), Glioma & glioblastoma, Prostate cancer.
- IdeaA standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics
Shares The brain: barrier and sanctuary, Glioma & glioblastoma, HER2-positive breast cancer.
- Key paperSingh 2004: identification of human brain tumour initiating cells
Shares Bao 2006: glioma stem cells resist radiotherapy by activating the DNA damage response, Glioma & glioblastoma.
- IdeaRead the spinal fluid to track brain tumours without opening the skull
Shares The brain: barrier and sanctuary, Glioma & glioblastoma, HER2-positive breast cancer.
cancers
technologies
targets
drugs
ApprovedADC
Trastuzumab emtansine · Kadcyla